Evolution, geographic spreading, and demographic distribution of Enterovirus D68.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
05 2022
Historique:
received: 24 10 2021
accepted: 10 04 2022
revised: 21 06 2022
pubmed: 1 6 2022
medline: 24 6 2022
entrez: 31 5 2022
Statut: epublish

Résumé

Worldwide outbreaks of enterovirus D68 (EV-D68) in 2014 and 2016 have caused serious respiratory and neurological disease. We collected samples from several European countries during the 2018 outbreak and determined 53 near full-length genome ('whole genome') sequences. These sequences were combined with 718 whole genome and 1,987 VP1-gene publicly available sequences. In 2018, circulating strains clustered into multiple subgroups in the B3 and A2 subclades, with different phylogenetic origins. Clusters in subclade B3 emerged from strains circulating primarily in the US and Europe in 2016, though some had deeper roots linking to Asian strains, while clusters in A2 traced back to strains detected in East Asia in 2015-2016. In 2018, all sequences from the USA formed a distinct subgroup, containing only three non-US samples. Alongside the varied origins of seasonal strains, we found that diversification of these variants begins up to 18 months prior to the first diagnostic detection during a EV-D68 season. EV-D68 displays strong signs of continuous antigenic evolution and all 2018 A2 strains had novel patterns in the putative neutralizing epitopes in the BC- and DE-loops. The pattern in the BC-loop of the USA B3 subgroup had not been detected on that continent before. Patients with EV-D68 in subclade A2 were significantly older than patients with a B3 subclade virus. In contrast to other subclades, the age distribution of A2 is distinctly bimodal and was found primarily among children and in the elderly. We hypothesize that EV-D68's rapid evolution of surface proteins, extensive diversity, and high rate of geographic mixing could be explained by substantial reinfection of adults. Better understanding of evolution and immunity across diverse viral pathogens, including EV-D68 and SARS-CoV-2, is critical to pandemic preparedness in the future.

Identifiants

pubmed: 35639811
doi: 10.1371/journal.ppat.1010515
pii: PPATHOGENS-D-21-02040
pmc: PMC9212145
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1010515

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Sci Rep. 2019 Apr 15;9(1):6073
pubmed: 30988475
J Clin Virol. 2011 Oct;52(2):103-6
pubmed: 21802981
mBio. 2019 Aug 13;10(4):
pubmed: 31409689
Pediatr Int. 2019 Aug;61(8):768-776
pubmed: 31136073
J Clin Virol. 2015 Aug;69:117-21
pubmed: 26209392
J Med Virol. 2010 Nov;82(11):1940-9
pubmed: 20872722
Emerg Microbes Infect. 2017 May 10;6(5):e32
pubmed: 28487560
J Clin Virol. 2019 Apr;113:24-26
pubmed: 30825833
Euro Surveill. 2016 May 12;21(19):
pubmed: 27195770
Euro Surveill. 2018 Nov;23(46):
pubmed: 30458915
Science. 2018 Aug 24;361(6404):800-803
pubmed: 30139872
J Gen Virol. 2012 Sep;93(Pt 9):1952-1958
pubmed: 22694903
Proc Natl Acad Sci U S A. 2018 Mar 20;115(12):3078-3083
pubmed: 29507246
Euro Surveill. 2018 Sep;23(37):
pubmed: 30229724
Viruses. 2021 Aug 13;13(8):
pubmed: 34452471
Nature. 1985 Sep 12-18;317(6033):145-53
pubmed: 2993920
Sci Transl Med. 2021 Mar 10;13(584):
pubmed: 33692131
Emerg Microbes Infect. 2018 Jun 6;7(1):99
pubmed: 29872035
Nat Rev Microbiol. 2018 Jan;16(1):47-60
pubmed: 29081496
PLoS One. 2012;7(5):e35190
pubmed: 22586446
Science. 2015 Jan 2;347(6217):71-4
pubmed: 25554786
J Pediatric Infect Dis Soc. 2018 Dec 26;7(suppl_2):S49-S53
pubmed: 30590621
MMWR Surveill Summ. 2006 Sep 15;55(8):1-20
pubmed: 16971890
Euro Surveill. 2019 Jan;24(3):
pubmed: 30670143
MMWR Morb Mortal Wkly Rep. 2019 Mar 29;68(12):277-280
pubmed: 30921299
Virus Evol. 2019 Apr 24;5(1):vez007
pubmed: 31037220
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
J Clin Virol. 2015 Oct;71:1-9
pubmed: 26364237
J Virol. 2014 Mar;88(5):2374-84
pubmed: 24371050
Emerg Infect Dis. 2019 Jun;25(6):1200-1203
pubmed: 30855226
PLoS One. 2015 Dec 02;10(12):e0144208
pubmed: 26630383
Euro Surveill. 2016 May 12;21(19):
pubmed: 27195917
Euro Surveill. 2019 Aug;24(35):
pubmed: 31481149
MMWR Morb Mortal Wkly Rep. 2011 Sep 30;60(38):1301-4
pubmed: 21956405
Viruses. 2019 Sep 04;11(9):
pubmed: 31487952
Sci Rep. 2016 Apr 28;6:25147
pubmed: 27121085
Euro Surveill. 2019 Feb;24(7):
pubmed: 30782269
Nature. 2015 Jul 9;523(7559):217-20
pubmed: 26053121
Emerg Infect Dis. 2019 Mar;25(3):585-588
pubmed: 30789123
Emerg Infect Dis. 2019 Sep;25(9):1676-1682
pubmed: 31407660
Am J Epidemiol. 1967 Mar;85(2):297-310
pubmed: 4960233
Lancet Infect Dis. 2016 May;16(5):e64-e75
pubmed: 26929196
Philos Trans R Soc Lond B Biol Sci. 1995 Jul 29;349(1327):25-31
pubmed: 8748016

Auteurs

Emma B Hodcroft (EB)

Biozentrum, University of Basel, Basel, Switzerland.
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Swiss Institute of Bioinformatics, Basel, Switzerland.

Robert Dyrdak (R)

Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.

Cristina Andrés (C)

Respiratory Viruses Unit, Virology Section, Microbiology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

Adrian Egli (A)

Clinical Bacteriology and Mycology, University Hospital Basel, Basel, Switzerland.
Applied Microbiology Research, Department of Biomedicine, University of Basel, Basel, Switzerland.

Josiane Reist (J)

Clinical Bacteriology and Mycology, University Hospital Basel, Basel, Switzerland.
Applied Microbiology Research, Department of Biomedicine, University of Basel, Basel, Switzerland.

Diego García Martínez de Artola (D)

Department of Clinical Microbiology, Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain.

Julia Alcoba-Flórez (J)

Department of Clinical Microbiology, Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain.

Hubert G M Niesters (HGM)

University of Groningen, University Medical Center Groningen, Department of Medical Microbiology, Division of Clinical Virology, Groningen, The Netherlands.

Andrés Antón (A)

Respiratory Viruses Unit, Virology Section, Microbiology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

Randy Poelman (R)

University of Groningen, University Medical Center Groningen, Department of Medical Microbiology, Division of Clinical Virology, Groningen, The Netherlands.

Marijke Reynders (M)

Unit of Molecular Microbiology, Medical Microbiology, Department of Laboratory Medicine, AZ Sint-Jan Brugge AV, Bruges, Belgium.

Elke Wollants (E)

KU Leuven, Rega Institute, Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical & Epidemiological Virology, Leuven, Belgium.

Richard A Neher (RA)

Biozentrum, University of Basel, Basel, Switzerland.
Swiss Institute of Bioinformatics, Basel, Switzerland.

Jan Albert (J)

Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, Sweden.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH